Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-56136379 + entecavir
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-56136379 + entecavir is an oral, investigational combination for chronic hepatitis B virus (HBV) infection. **JNJ-56136379** is a *hepatitis B virus capsid assembly modulator* that interferes with the formation of functional viral capsids, inhibiting HBV replication. **Entecavir** is a *nucleoside analogue* that inhibits HBV DNA polymerase, decreasing viral DNA synthesis. The combination aims to suppress HBV replication through dual mechanisms, and is under clinical investigation for use in patients with chronic hepatitis B, including those with or without prior nucleos(t)ide analogue treatment[1][3][5][2][4][6].
- Other names
- entecavir
02
Targets
HBc (Hepatitis B virus core protein)HBV Pol (Hepatitis B virus polymerase)UGT1A1 (UDP-glucuronosyltransferase 1A1)UGT2B7 (UDP-glucuronosyltransferase 2B7)HBV capsid (Hepatitis B virus capsid)
Beyond the preview
Go deeper on JNJ-56136379 + entecavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-56136379 + entecavir.